Industri

PharmaEssentia’s Besremi receives FDA approval for ET

This marks the first FDA-approved treatment for ET in nearly 30 years. The appro...

Kazia closes oversubscribed offering to fund paxalisib’...

These proceeds will support the planned and ongoing studies of Kazia’s lead inve...

Eli Lilly to acquire Merida Biosciences for up to $2.87...

Deal gives Lilly access to Merida’s precision technology targeting disease-caus...

Express Pharma September 2026

India's Foremost Pharma & Biotech Magazine ~ India's Race For The CDMO Crown Th...

Sun Pharma joins US drug pricing deal, gets tariff relief

The company will offer MFN pricing to state Medicaid programmes and for future ...

How Correctional Administrators Can Prepare Themselves,...

One of the many issues that correctional administrators are facing today is the ...

Panel Discussion: Are we measuring FR&D success the rig...

FDD Conclave 2026 | 6th August 2026 | Ahmedabad Connect The post Panel Discussi...

Dr Abhijit Gothoskar, Technical Expert, Sigachi Industries

FDD Conclave 2026 | 6th August 2026 | Ahmedabad Connect The post Dr Abhijit Got...

Dr Ajay Jaysingh Khopade, Site Head R&D, VP and Head-Fo...

FDD Conclave 2026 | 6th August 2026 | Ahmedabad Connect The post Dr Ajay Jaysin...

Ms Ritu Laddha, Sr VP & Cluster Head, Zydus Lifesciences

FDD Conclave 2026 | 6th August 2026 | Ahmedabad Connect The post Ms Ritu Laddha...

Panel Discussion: AI, talent and technology: The new FR...

FDD Conclave 2026 | 6th August 2026 | Ahmedabad Connect The post Panel Discuss...

Dr Richa Dayaramani, Scientist Grade F, NIPER Ahmedabad

FDD Conclave 2026 | 6th August 2026 | Ahmedabad Connect The post Dr Richa Daya...

Panel Discussion: Ahmedabad’s innovation edge: Where sc...

FDD Conclave 2026 | 6th August 2026 | Ahmedabad Connect The post Panel Discuss...

BioE3 at 2: From policy push to industry scale

Podcast with Dr. Rahul Warke, Ph.D., Director, Research and Development (Microb...

Teva Pharmaceuticals to acquire BioXcel assets for up t...

The agreement arises as part of BioXcel Therapeutics’ voluntary Chapter 11 proce...

AusperBio raises $120m to progress hepatitis B therapies

The round was led by an undisclosed strategic investor. New investor RA Capital ...